,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['db04']
excited to see db04. our study suggested her2low bc may be more sensitive to chemotherapy and support further development of anti her2low agent.
no sig racial diff in her2 low prevalence. no sig diff in oncotype rs between her2-low and her2 zero. #asco22 
Hem/Onc Fellow @RoswellPark 
Interested in patient centered care, survivorship/policy/outcome research

SoochowUniv' MD 14,  MPH 16 @yalesph ,  IM 2020 @msm_msw